OncoMatch/Clinical Trials/NCT02619448
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
Is NCT02619448 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Carboplatin and Paclitaxel for non-small cell lung cancer.
Treatment: Carboplatin · Paclitaxel — The standard treatment for patients with Non-Small Cell Lung Cancer (NSCLC) and clinically negative lymph nodes remains surgery per current guidelines. Five year survival for patients with stage I non-small cell lung cancer is generally greater than 50% after surgery. Many of these patients have heart and lung issues or other diseases which keep them from undergoing curative surgery. Studies have shown that majority of these patients die from their cancer and not from their other diseases. This is the reason for treating early stage lung cancer patients with definitive therapy, when they cannot have surgery. This study will enroll twelve subjects to evaluate the side effects of this treatment, and decide if it is a good option for the patients that cannot have surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage T1BN0M0, T2AN0M0, T2BN0M0 (AJCC 7th edition of TNM classification)
Excluded: Stage NODE POSITIVE, IV
Solitary [T1bN0M0, T2aN0M0, T2bN0M0] lesion measuring 2-7cm in size. Staging is per AJCC 7th edition of TNM classification.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- SUNY Upstate Medical University · Syracuse, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify